PL Mini (LS-4000) Wins Pharmacy Innovation Product of the Year Award 2023

Reinventing POCT to enable faster clinical interventions when it matters most

Enhanced solution for in vitro immunological detection

I am very excited by the wider opportunities that working with PremaLabs Diagnostics can bring in realising my vision for a more joined-up public and private healthcare ecosystem

Reshma Malde, Superintendent Pharmacist, John Bell & Croyden

PremaLabs Diagnostics’ point of care tests utilise innovative time resolved florescence immunoassay (TRFIA) technology, offering a broad panel range of analytes that are designed to support the myriad of established and new settings for rapid healthcare testing.

Tony Cambridge, POCTinnovators.com

The partnership with PremaLabs Diagnostics has exceeded our expectations, and we are excited about the possibilities it holds for future collaborations. The dedication and professionalism demonstrated by their team have been exemplary throughout our engagement. Their commitment to providing high-quality testing services, coupled with their focus on innovation, aligns perfectly with our organisation's goals and values.

Johann van Zyl CEO, Cornerstone Healthcare Group

It is important that Care Homes have access to tests that indicate conditions which may be affecting individuals. I believe that testing has to be the cornerstone of good quality, appropriate care and it is for this reason that I am supporting PremaLabs Diagnostics with their NAb testing programme.

Professor Martin Green, Chief Executive, Care England

Point of Care Testing (POCT) is still a relatively new area of diagnostics, with the majority of tests being analysed by central laboratories, and some results taking days or even weeks to come back. It’s usual for only one or two tests to be compatible with one POCT analyser device. Where we differ is that we have a total of 37 CE and UKCA marked tests that can be used with a single device.

We’re all used to lateral flow tests, thanks to Covid-19. But unlike the Covid-19 Antigen LFTs which give a positive/negative result, our tests use innovative TRFIA technology, giving quantitative laboratory-grade results in under 15 minutes when used in conjunction with any one of our three analyser devices.

Tests typically use whole-blood, plasma or serum specimens; however, sixteen of the 37 tests require only capillary (finger prick) blood specimens, making it even easier to collect the sample and obtain lab-comparable results in a matter of minutes – from virtually anywhere!